Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diagnostics company Vermillion has reported the renewal of a long-standing collaboration with Johns Hopkins University on the development of novel biomarkers that can be applied toward disease detection, classification and monitoring of prevalent cancers, including ovarian, breast and prostate.
Subscribe to our email newsletter
Under the terms of the collaboration, Vermillion will continue to provide financial support, technical assistance and access to its advanced technology platforms, while Johns Hopkins will continue to contribute cancer serum samples and the clinical and scientific expertise of its physicians and scientists. Vermillion will have access to exclusive commercial rights to the discoveries made through the partnership.
Eric Fung, chief scientific officer of Vermillion, said: “This dynamic collaboration has led to the development of our ovarian tumor triage test that has the potential to significantly improve patient outcomes. We look forward to expanding this steadfast relationship.”